High-dose FOLFIRI in Advanced Colorectal Cancer Patients With Wild-type UGT1A1*6 and *28

• Status: Recruiting
• Trial end date: 2022-03-01

Summary

This trial aims to evaluate the efficacy, safety of high-dose FOLFIRI regimen in advanced colorectal cancer patients with wild-type UGT1A1*6 and *28.

• Phase: Phase 2

Details

• Lead Sponsor: Shanghai Changzheng Hospital
• Treatments: Camptothecin; Fluorouracil; Irinotecan